Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Core Points - Calidi Biotherapeutics, Inc. has entered into a definitive securities purchase agreement for the sale of 3,325,000 shares of common stock at $0.65 per share, with an option for the investor to purchase pre-funded warrants for up to 2,728,000 shares at $0.649 each [1][3] - The company will also issue series G warrants in a concurrent private placement, allowing the purchase of up to 6,053,000 shares at an exercise price of $0.6954, exercisable six months after issuance [3][7] - The gross proceeds from both offerings are expected to be approximately $3.9 million, which will be used for working capital and to advance pre-clinical and clinical programs [5][6] Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted immunotherapies using proprietary technology to enhance the immune system's ability to fight cancer [9] - The company utilizes allogeneic stem cells to deliver oncolytic viruses for various oncology indications, including high-grade gliomas and solid tumors, aiming to improve efficacy and patient safety [9]